PIPE-307 Advances Milestone: Continuum Therapeutics Hits Full Patient Recruitment Target for Landmark RRMS Study

Continuum Therapeutics (NASDAQ: CTNM) has successfully wrapped up patient recruitment for its Phase 2 VISTA trial, bringing 168 relapsing-remitting multiple sclerosis (RRMS) patients into the study ahead of the original timeline. The trial is evaluating PIPE-307, a potentially first-in-class M1 receptor antagonist being developed in collaboration with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson.

Trial Details and Clinical Significance

The randomized, double-blind, placebo-controlled Phase 2 trial represents a pivotal moment for PIPE-307’s development trajectory. The study is specifically designed to investigate whether the drug candidate can drive remyelination—a key mechanism for potentially transforming RRMS treatment—while simultaneously collecting safety and efficacy data across multiple clinical and imaging endpoints.

The completion of full recruitment by December 2024 positions Continuum ahead of its original enrollment schedule. According to Stephen Huhn, Chief Medical Officer at Continuum Therapeutics, reaching this enrollment milestone underscores investor and investigator confidence in the program’s potential. “The VISTA trial is structured to demonstrate evidence that PIPE-307 could represent a meaningful shift in how we approach RRMS management,” Huhn noted.

What’s Next: Timeline and Expectations

The final patient is projected to complete the trial during the third quarter of 2025, setting the stage for topline data analysis. Successful results could position PIPE-307 as a differentiated therapeutic option for RRMS patients with significant unmet medical needs.

Broader Context: Continuum’s Pipeline

Beyond PIPE-307, Continuum is advancing other internally-developed programs targeting neuroscience, inflammation and immunology indications. The company’s pipeline includes PIPE-791, an LPA1 receptor antagonist currently in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.

The successful enrollment achievement reflects both the clinical promise of PIPE-307 and the broader momentum in neuroscience-focused drug development, where novel mechanisms targeting remyelination remain a critical research frontier for progressive neurological diseases.